Why Reality Does Not Support The Recent Rally [View article]
but what is the fundamental value of $SPY, what if current price is much lower than it should be? we already got big down last oct, so the market can well go higher into year-end
3 Biotechs With Recent Intensive Insider Buying [View article]
For $INO, the history should there are much larger insider selling than insider buying, so why you want to long it. All those insider buying are in small amount.
Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to Neutral and removing it from its Focus List due to the uncertainty over the discrepancies in its Phase II study of bavituximab. The firm also skewered its price target on the shares, slashing it to $0.70 from $9. [View news story]
could be just kill those who carry margins and then they bring it up? These kind of biotech or biopharm stocks are too risky
Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to Neutral and removing it from its Focus List due to the uncertainty over the discrepancies in its Phase II study of bavituximab. The firm also skewered its price target on the shares, slashing it to $0.70 from $9. [View news story]
EU Summit Agreement Bogus: Global Bear Market To Resume [View article]
Hi james, I would very much like if you can say when you long the VXX and your time horizon otherwise it is misleading and other people follow you will lose money a lot since VXX's decay. It is very risky to long the calls since it will eventually goes to 0.
Just do people a favor and they will appreciate it.
Why Reality Does Not Support The Recent Rally [View article]
Why VIX ETPs Have Been Underperforming [View article]
The Collapse, Death, And End Of The Euro [View article]
The 'New' Celsion Could Be Worth $4 A Share [View article]
3 Biotechs With Recent Intensive Insider Buying [View article]
Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to Neutral and removing it from its Focus List due to the uncertainty over the discrepancies in its Phase II study of bavituximab. The firm also skewered its price target on the shares, slashing it to $0.70 from $9. [View news story]
Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to Neutral and removing it from its Focus List due to the uncertainty over the discrepancies in its Phase II study of bavituximab. The firm also skewered its price target on the shares, slashing it to $0.70 from $9. [View news story]
Starbucks: Short The Bubble [View article]
EU Summit Agreement Bogus: Global Bear Market To Resume [View article]
Just do people a favor and they will appreciate it.
Thursday Options Recap [View article]
The Eurozone: Zero Chance Of Break-Up But Caution Is Advisable [View article]